The value of combined Quantitative MRI for Treatment Response Assessment in head and neck cancer patients receiving (Chemo)radiotherapy. - QTRAC

Amsterdam UMC0 个研究点目标入组 30 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•1) Newly diagnosed tumours classified as stage T2-4 N0-2 located in the larynx,
•oropharynx or hypopharynx
•(unknown primary and oral cavity are not eligible)
•2) Histopathological diagnosis of invasive squamous cell carcinoma in the
•primary tumour
•3) (Chemo)Radiotherapy planned to start within 6 weeks from baseline imaging of
•tumour assessment
•4) No distant metastasis (M0)
•5) WHO performance status 0-2
•6) >= 18 years of age
•7) Written informed consent signed by the patient

•Each of the following criteria will result in exclusion from participation in
•this study:
•1) Age < 18 years
•2) Pregnancy
•3) Patients carrying a pacemaker, or unable to undergo an MRI on a 3T MRI
•4) Primary tumour of the oral cavity or unknown primary tumour
•5) Prior or current anticancer treatment to the head and neck area (e.g.
•radical attempted or tumour
•reductive surgery, neo-adjuvant or concomitant chemotherapy, EGFR inhibitors or
•radiotherapy),
•except for endoscopic glottic laser micro surgery.
•6) Current participation in any other interventional clinical study.
•7) History of previous malignancy within the last 3 years.

发起方

Amsterdam UMC